NCT03819296 2026-03-11
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
8 trialsNCT06646016 2025-12-26
EPIC
Therakos LLC
Phase 2 Withdrawn
NCT04407247 2025-12-23
Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06815003 2025-06-27
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
Phase 2 Recruiting
NCT06475820 2024-08-23
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Active not recruiting
NCT02723006 2024-03-05
Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma
Takeda
Phase 1 Terminated
NCT05515029 2023-09-28
Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Active not recruiting
NCT02768532 2023-06-15
VEDO-PREDIRESP
Centre Hospitalier Universitaire de Saint Etienne
Phase 4 Terminated